Get the Stockscreener App
23.46
36.06%
-13.24
After Hours:
24.13
0.665
+2.83%
Summit Therapeutics Inc stock is traded at $23.46, with a volume of 24.56M.
It is down -36.06% in the last 24 hours and up +15.93% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$36.70
Open:
$34.48
24h Volume:
24.56M
Relative Volume:
7.16
Market Cap:
$18.60B
Revenue:
$956.00K
Net Income/Loss:
$-196.68M
P/E Ratio:
-97.77
EPS:
-0.24
Net Cash Flow:
$-113.02M
1W Performance:
-4.65%
1M Performance:
+15.93%
6M Performance:
+10.37%
1Y Performance:
+560.99%
1-Day Range:
$22.22
$35.92
1-Week Range:
$22.22
$36.91
52-Week Range:
$2.10
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
23.46 | 18.60B | 956.00K | -196.68M | -113.02M | -0.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Press Release Distribution & PR Platform - ACCESS Newswire
Akeso survival data for ivonescimab misses expectations, STAT says - Yahoo Finance
Summit Therapeutics: New Ivonescimab Data Raise Concerns (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics Stock Plummets Amid Study Setback - Evrim Ağacı
BioNTech And Summit Therapeutics Stocks Fluctuate Dramatically - Evrim Ağacı
Summit Therapeutics (SMMT) Reports Ivonescimab's Approval in Chi - GuruFocus
Summit Therapeutics (SMMT) Observes Notable Progress with Ivones - GuruFocus
Summit Therapeutics, Saia, And T-Mobile US Take A Hit In Trading - Finimize
Akeso (AKESF) and Summit Therapeutics (SMMT) See Stock Declines After Drug Data Release | BNTX Stock News - GuruFocus
Summit Therapeutics Receives Buy Rating Amid Promising Ivonescimab Developments and Strategic Trials - TipRanks
Merck (MRK) Reacts to Summit Therapeutics' Lung Cancer Therapy D - GuruFocus
Market Today: Alphabet's Earnings Boost Tech, Summit Therapeutics Plummets - GuruFocus
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today - Mitrade
Summit Therapeutics (SMMT) Price Target Raised Amid Positive Dru - GuruFocus
Summit Therapeutics (SMMT) Sees Stock Drop Despite Positive Drug - GuruFocus
Summit Therapeutics Gets Approval From China's Health Authority for Second Use of Ivonescimab - marketscreener.com
Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial - Fierce Pharma
Citi says buy Summit amid ‘significant market confusion’ - TipRanks
Summit Therapeutics (SMMT) Shares Resume Trading After Drug Appr - GuruFocus
Summit Therapeutics shares tumble following interim analysis By Investing.com - Investing.com Nigeria
Merck gains after latest survival data for Summit’s cancer drug - MSN
Merck stock gains on Summit data for cancer drug (MRK:NYSE) - Seeking Alpha
Summit Therapeutics to resume trading at 3:20 pm ET - TipRanks
What's Going On With Summit Therapeutics Stock On Friday?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Summit Therapeutics (SMMT) Schedules Q1 2025 Earnings Call - GuruFocus
Summit Therapeutics shares tumble following interim analysis - Investing.com Australia
Summit Therapeutics (SMMT): Interim OS Analysis Requested from Chinese Health Authorities Shows Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive A - StreetInsider
Summit Therapeutics (SMMT) Stock Soars After Phase III Trial Suc - GuruFocus
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso - marketscreener.com
Summit Therapeutics (SMMT) Gains Attention Amid New Drug Approva - GuruFocus
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic - Investing.com India
Wells says Summit, Akeso data ‘not the bull case,’ but not ‘bear case either’ - TipRanks
Summit Therapeutics (SMMT) Plummets After FDA Approval News - GuruFocus
Summit plunges 35%; partner Akesso wins FDA nod for cancer drug - MSN
Summit stock falls, partner Akesso wins FDA nod (SMMT:NASDAQ) - Seeking Alpha
Jefferies uncovers China approval for Summit Therapeutics, ups target - TipRanks
Summit Therapeutics : Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) #2 - marketscreener.com
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025 - Business Wire
Summit Therapeutics (SMMT) Stock Rises on Positive Trial Data - GuruFocus
Summit Therapeutics gains on cancer trial data (SMMT:NASDAQ) - Seeking Alpha
H.C. Wainwright maintains Buy on Summit Therapeutics stock By Investing.com - Investing.com Canada
Summit Therapeutics stock soars to all-time high of $34.05 By Investing.com - Investing.com India
Summit Therapeutics stock soars to all-time high of $34.05 - Investing.com
Summit Therapeutics (SMMT) Surges on Positive Lung Cancer Treatm - GuruFocus
H.C. Wainwright maintains Buy on Summit Therapeutics stock - Investing.com
Mitchell Kapoor Reaffirms Buy Rating for Summit Therapeutics Amid Promising Ivonescimab Trial Results - TipRanks
Summit Therapeutics (SMMT) Surges on Positive Lung Cancer Treatment Results - GuruFocus
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial - MSN
Summit Therapeutics Retail Traders Stoked As Stock Surges On Promising Cancer Drug Trial By Stocktwits - Investing.com India
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
15.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):